image
Healthcare - Medical - Devices - NYSE - US
$ 100.15
-2.14 %
$ 5.72 B
Market Cap
-44.12
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one GKOS stock under the worst case scenario is HIDDEN Compared to the current market price of 100 USD, Glaukos Corporation is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one GKOS stock under the base case scenario is HIDDEN Compared to the current market price of 100 USD, Glaukos Corporation is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one GKOS stock under the best case scenario is HIDDEN Compared to the current market price of 100 USD, Glaukos Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart GKOS

image
$170.0$170.0$160.0$160.0$150.0$150.0$140.0$140.0$130.0$130.0$120.0$120.0$110.0$110.0$100.0$100.0$90.0$90.0$80.0$80.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
383 M REVENUE
21.85%
-122 M OPERATING INCOME
4.92%
-146 M NET INCOME
-8.70%
-61.3 M OPERATING CASH FLOW
-6.16%
47.8 M INVESTING CASH FLOW
239.35%
91.5 M FINANCING CASH FLOW
508.56%
107 M REVENUE
1.10%
-20.7 M OPERATING INCOME
27.87%
-18.1 M NET INCOME
45.96%
-18.5 M OPERATING CASH FLOW
-3653.06%
-36.9 M INVESTING CASH FLOW
-313.46%
1.95 M FINANCING CASH FLOW
-96.76%
Balance Sheet Glaukos Corporation
image
Current Assets 450 M
Cash & Short-Term Investments 319 M
Receivables 60.7 M
Other Current Assets 70.1 M
Non-Current Assets 525 M
Long-Term Investments 0
PP&E 170 M
Other Non-Current Assets 355 M
32.72 %6.23 %7.19 %17.43 %36.42 %Total Assets$974.8m
Current Liabilities 75.1 M
Accounts Payable 13 M
Short-Term Debt 0
Other Current Liabilities 62.1 M
Non-Current Liabilities 133 M
Long-Term Debt 0
Other Non-Current Liabilities 133 M
6.27 %29.88 %63.85 %Total Liabilities$207.8m
EFFICIENCY
Earnings Waterfall Glaukos Corporation
image
Revenue 383 M
Cost Of Revenue 94 M
Gross Profit 289 M
Operating Expenses 412 M
Operating Income -122 M
Other Expenses 24 M
Net Income -146 M
400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)383m(94m)289m(412m)(122m)(24m)(146m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
75.48% GROSS MARGIN
75.48%
-31.91% OPERATING MARGIN
-31.91%
-38.17% NET MARGIN
-38.17%
-19.09% ROE
-19.09%
-15.02% ROA
-15.02%
-13.67% ROIC
-13.67%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Glaukos Corporation
image
20m20m10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)(80m)(80m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -146 M
Depreciation & Amortization 39.9 M
Capital Expenditures -6.3 M
Stock-Based Compensation 50.2 M
Change in Working Capital 0
Others -4.86 M
Free Cash Flow -67.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Glaukos Corporation
image
Wall Street analysts predict an average 1-year price target for GKOS of $149 , with forecasts ranging from a low of $120 to a high of $185 .
GKOS Lowest Price Target Wall Street Target
120 USD 19.82%
GKOS Average Price Target Wall Street Target
149 USD 48.78%
GKOS Highest Price Target Wall Street Target
185 USD 84.72%
Price
Max Price Target
Min Price Target
Average Price Target
2002001801801601601401401201201001008080Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Glaukos Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
3.16 M USD 3
6-9 MONTHS
2.61 M USD 2
9-12 MONTHS
5.1 M USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
What Makes Glaukos (GKOS) a New Buy Stock Glaukos (GKOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 2 weeks ago
Can Glaukos (GKOS) Climb 34.4% to Reach the Level Wall Street Analysts Expect? The mean of analysts' price targets for Glaukos (GKOS) points to a 34.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com - 3 weeks ago
Here's Why You Should Retain Glaukos Stock in Your Portfolio GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism. zacks.com - 1 month ago
Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 2 months ago
GKOS Stock Falls Despite Q1 Earnings & Revenue Beat, Margins Decline Glaukos' first-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern. zacks.com - 2 months ago
Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript Glaukos Corporation (NYSE:GKOS ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Chris Lewis - Vice President of Investor Relations and Corporate Affairs Tom Burns - Chairman and CEO Joe Gilliam - President and COO Alex Thurman - CFO Conference Call Participants Tom Stephan - Stifel Ryan Zimmerman - BTIG Larry Biegelsen - Wells Fargo Allen Gong - J.P. Morgan David Saxon - Needham Adam Maeder - Piper Sandler Joanne Wuensch - Citibank Margaret Andrew - William Blair Richard Newitter - Truist Securities Michael Sarcone - Jefferies Anthony Petrone - Mizzou Group Danielle Antalffy - UBS Patrick Wood - Morgan Stanley Operator Welcome to Glaukos Corporation First Quarter 2025 Financial Results Conference Call. seekingalpha.com - 2 months ago
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates Glaukos (GKOS) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.70 per share a year ago. zacks.com - 2 months ago
Glaukos Announces First Quarter 2025 Financial Results ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2025. Key highlights include: Record net sales of $106.7 million in Q1 2025 increased 25% year-over-year on a reported basis and 26% year-over-year on a constant currency basis. Glaucoma record net. businesswire.com - 2 months ago
Baron Health Care Fund Q1 2025 Top Contributors And Detractors Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, insulating it from tariff impacts. seekingalpha.com - 2 months ago
Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 months ago
Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 25-28, 2025 in Los Angeles, CA. Glaukos will be exhibiting onsite at booth #2227. businesswire.com - 2 months ago
Glaukos Announces the Release of its 2024 Sustainability Report ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2024 Sustainability Report. The report highlights the company's continued commitment and progress on its key corporate sustainability initiatives. The Sustainability Report can be found on the company's website here. “I am prou. businesswire.com - 2 months ago
8. Profile Summary

Glaukos Corporation GKOS

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 5.72 B
Dividend Yield 0.00%
Description Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Contact 229 Avenida Fabricante, Aliso Viejo, CA, 92672 https://www.glaukos.com
IPO Date June 25, 2015
Employees 995
Officers Ms. Diana A. Scherer Vice President of Compliance & Deputy General Counsel Mr. Chris M. Calcaterra Executive Vice President of Global Commercial Operations Mr. L. Jay Katz FACS, M.D. Chief Medical Officer Mr. Joseph E. Gilliam President & Chief Operating Officer Ms. Michele M. Allegretto Senior Vice President of Human Resources Mr. Robert L. Davis J.D. Senior Vice President, General Counsel & Business Development Dr. Tomas Navratil Ph.D. Chief Development Officer Mr. Alex R. Thurman Senior Vice President & Chief Financial Officer Mr. Christopher William Lewis Vice President of Investor Relations & Corporate Affairs Mr. Thomas William Burns Chairman & Chief Executive Officer